NTLA Profile
Intellia Therapeutics Inc (NTLA) is a biotechnology company focused on developing curative treatments using CRISPR/Cas9 gene editing technology. The company is headquartered in Cambridge, Massachusetts and was founded in 2014.
Intellia's primary focus is on developing gene therapies for genetic diseases. The company's proprietary technology enables precise, targeted editing of the genome to potentially cure genetic diseases. The company is developing a broad pipeline of potential therapies across a range of diseases, including genetic diseases, cancer, and viral infections.
Intellia's lead program is a potential treatment for transthyretin amyloidosis (ATTR), a rare genetic disease caused by the buildup of misfolded transthyretin protein in tissues and organs. The company is also developing potential treatments for sickle cell disease and cancer, among other indications.
Intellia has partnerships with a number of pharmaceutical and biotechnology companies, including Novartis, Regeneron, and Ospedale San Raffaele. These partnerships provide Intellia with additional resources and expertise to develop its pipeline of potential therapies.
|
